Pörssitiedote
Faron Pharmaceuticals Ltd: Director Dealing
Faron Pharmaceuticals Ltd | Company announcement | July 02, 2025 at 13:00:00 EEST
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Mr. Tuomo Pätsi, Non-Executive Chairman of the Company, acquired 21,500 ordinary shares in Faron at price of €2.435 per share on 30 June 2025. Following this purchase, Mr. Pätsi directly holds 53,265 ordinary shares in the Company, representing 0.05 per cent. of the voting rights in the Company.
Further details are set out in the Notification of Dealing Form below.
Director Holding prior to purchase Number of ordinary shares Resultant interest in ordinary shares in the Company Resultant percentage of voting rights in the Company
Tuomo Pätsi 31,765 21,500 53,265 0.05%